Puromycin Aminonucleoside: Gold-Standard Nephrotoxic Agent for Podocyte Injury Models

Executive Summary: Puromycin aminonucleoside (CAS 58-60-6) is the aminonucleoside moiety of the antibiotic puromycin and is widely used to induce nephrotic syndrome in animal models (APExBIO). It causes proteinuria and glomerular lesions by disrupting podocyte morphology and the glomerular filtration barrier (Yeast Extract). Its uptake by renal cells is pH-dependent and transporter-mediated, notably via PMAT. Puromycin aminonucleoside demonstrates well-characterized cytotoxicity in in vitro systems, with documented IC50 values and solubility profiles. This compound enables reproducible modeling of focal segmental glomerulosclerosis (FSGS) and is a foundational tool for translational nephrology research (Egg White Lysozyme).

Biological Rationale

Puromycin aminonucleoside is a synthetic aminonucleoside derived from the antibiotic puromycin. It selectively targets podocytes, specialized cells integral to the glomerular filtration barrier in kidneys (APExBIO). Podocyte injury is a key driver of proteinuria and nephrotic syndrome, both in human disease and experimental models. The compound’s nephrotoxic profile makes it a preferred agent for inducing podocyte dysfunction, proteinuria, and glomerular lesions in vivo. These features are central for modeling focal segmental glomerulosclerosis (FSGS) and related renal pathologies (Yeast Extract). By mimicking structural and functional defects observed in human nephrotic syndromes, puromycin aminonucleoside establishes a translational bridge for evaluating drugs, biomarkers, and pathomechanisms.

Mechanism of Action of Puromycin aminonucleoside

Puromycin aminonucleoside exerts cytotoxic effects by disrupting podocyte cytoskeletal integrity. This leads to loss of cellular microvilli, effacement of foot-processes, and breakdown of the slit diaphragm—critical elements of the glomerular filtration barrier (Asenapine Smallmol). In vitro, the compound reduces the number and length of podocyte microvilli and alters actin organization. In vivo, administration in rats leads to marked proteinuria, lipid accumulation in mesangial cells, and histopathological changes consistent with FSGS. Uptake is mediated by organic cation transporters, especially the plasma membrane monoamine transporter (PMAT), with pH-dependent efficiency: uptake at pH 6.6 is fourfold higher than at pH 7.4 in PMAT-expressing cells. This transporter specificity partly explains cell-type selectivity and experimental outcomes (APExBIO).

Evidence & Benchmarks

• Induces reproducible proteinuria and glomerular lesions in rodent models used for nephrotic syndrome and FSGS research (APExBIO).
• Alters podocyte morphology in vitro by reducing microvilli density and disrupting actin cytoskeleton (Yeast Extract).
• Exhibits cytotoxicity in MDCK cells with IC50 values of 48.9 ± 2.8 μM (vector) and 122.1 ± 14.5 μM (PMAT-transfected) at specified pH conditions (Egg White Lysozyme).
• Demonstrates pH-dependent cellular uptake, with fourfold increase at pH 6.6 versus pH 7.4 in PMAT-expressing cells (APExBIO).
• Soluble at ≥14.45 mg/mL in DMSO, ≥29.4 mg/mL in ethanol, and ≥29.5 mg/mL in water (gentle warming), supporting versatile use in laboratory assays (APExBIO).
• Glomerular lesions induced closely resemble human FSGS, facilitating translational research into renal disease mechanisms (Asenapine Smallmol).
• Benchmark protocols and troubleshooting strategies for reproducible nephrotic injury modeling detailed in recent reviews (AS602801).

Applications, Limits & Misconceptions

Puromycin aminonucleoside is used as a nephrotoxic agent for:

• Modeling nephrotic syndrome and FSGS in rodents.
• Studying proteinuria, podocyte injury, and glomerular filtration barrier disruption.
• Evaluating cytotoxicity and transporter-mediated uptake in renal cell lines.
• Testing nephroprotective interventions and mechanistic studies of renal pathology.

Compared to older reviews, this article provides updated quantitative benchmarks and workflow integration details.

See also Egg White Lysozyme, which highlights solubility and uptake parameters; here, we extend discussion to practical workflow design and avoidance of typical pitfalls.

Common Pitfalls or Misconceptions

• Not all nephrotoxic agents induce FSGS-like lesions; puromycin aminonucleoside is specific for this application.
• Results are model- and species-dependent; rodent data may not extrapolate directly to human pathology.
• Overuse or incorrect dosing can lead to off-target toxicity and non-specific renal injury.
• Long-term storage of prepared solutions is discouraged; use fresh aliquots for reproducibility.
• Assuming all podocyte injuries induced are reversible—structural damage is often permanent at high doses.

Workflow Integration & Parameters

For experimental use, dissolve puromycin aminonucleoside to ≥14.45 mg/mL in DMSO, ≥29.4 mg/mL in ethanol, or ≥29.5 mg/mL in water with gentle warming (APExBIO). Store stock solutions below -20°C for several months; do not freeze working dilutions long-term. Administer to rodents at doses validated for nephrotic injury (see AS602801 for reference protocols). In vitro, select concentration ranges around reported IC50 values, adjusting for cell type and pH conditions. PMAT-transfected cell lines facilitate mechanistic studies of organic cation transporter-mediated uptake. Shipping is performed on blue ice for small molecules and dry ice for modified nucleotides. APExBIO supplies validated product (SKU A3740), supporting consistent results across laboratories.

Conclusion & Outlook

Puromycin aminonucleoside remains the benchmark nephrotoxic agent for modeling podocyte injury and nephrotic syndrome. Its mechanism, uptake specificity, and reproducible phenotypes make it indispensable for translational renal research. Emerging protocols and transporter studies will refine its applications. For detailed product specifications and ordering, see the APExBIO product page.